NCT03970252View on ClinicalTrials.gov

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

May 25, 2024

Study Completion Date

May 25, 2024

Conditions
Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Fluorouracil

Given IV

DRUG

Irinotecan

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Leucovorin

Given IV

DRUG

Leucovorin Calcium

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Oxaliplatin

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

NovoCure Ltd.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER